{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:28:00Z","timestamp":1707784080358},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,12]]},"DOI":"10.7759\/cureus.54066","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T14:36:50Z","timestamp":1707748610000},"source":"Crossref","is-referenced-by-count":0,"title":["Poor Prognosis in Low-Grade Endometrial Stromal Sarcoma With Cyclin-Dependent Kinase Inhibitor 2A Homozygous Deletion: A Case Study"],"prefix":"10.7759","author":[{"given":"Atsushi","family":"Mori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyosuke","family":"Kamijo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Sano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Muramoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaeko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.02.009","article-title":"Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes","volume":"171","author":"Gadducci A","year":"2023","unstructured":"Gadducci A, Multinu F, De Vitis LA, Cosio S, Carinelli S, Aletti GD. Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2023, 171:95-105. 10.1016\/j.ygyno.2023.02.009","journal-title":"Gynecol Oncol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000494225","article-title":"Low-grade endometrial stromal sarcoma - a review","volume":"41","author":"Thiel FC","year":"2018","unstructured":"Thiel FC, Halmen S. Low-grade endometrial stromal sarcoma - a review. Oncol Res Treat. 2018, 41:687-92. 10.1159\/000494225","journal-title":"Oncol Res Treat"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.12.032","article-title":"Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases","volume":"132","author":"Bai H","year":"2014","unstructured":"Bai H, Yang J, Cao D, et al.. Ovary and uterus-sparing procedures for low-grade endometrial stromal sarcoma: a retrospective study of 153 cases. Gynecol Oncol. 2014, 132:654-60. 10.1016\/j.ygyno.2013.12.032","journal-title":"Gynecol Oncol"},{"key":"ref4","unstructured":"NCCN guidelines version 1.2024 uterine neoplasms. (2024). Accessed. January 8, 2024: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1473&utm_medium=email&utm_source=transaction."},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2009.02.005","article-title":"The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study","volume":"144","author":"Dahhan T","year":"2009","unstructured":"Dahhan T, Fons G, Buist MR, Ten Kate FJ, van der Velden J. The efficacy of hormonal treatment for residual or recurrent low-grade endometrial stromal sarcoma. A retrospective study. Eur J Obstet Gynecol Reprod Biol. 2009, 144:80-4. 10.1016\/j.ejogrb.2009.02.005","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2005.11.010","article-title":"Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature","volume":"101","author":"Pink D","year":"2006","unstructured":"Pink D, Lindner T, Mrozek A, Kretzschmar A, Thuss-Patience PC, D\u00f6rken B, Reichardt P. Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol. 2006, 101:464-9. 10.1016\/j.ygyno.2005.11.010","journal-title":"Gynecol Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2007.06.011","article-title":"The management of patients with uterine sarcoma: a debated clinical challenge","volume":"65","author":"Gadducci A","year":"2008","unstructured":"Gadducci A, Cosio S, Romanini A, Genazzani AR. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol. 2008, 65:129-42. 10.1016\/j.critrevonc.2007.06.011","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12333","article-title":"Genetics of familial melanoma: 20 years after CDKN2A","volume":"28","author":"Aoude LG","year":"2015","unstructured":"Aoude LG, Wadt KA, Pritchard AL, Hayward NK. Genetics of familial melanoma: 20 years after CDKN2A. Pigment Cell Melanoma Res. 2015, 28:148-60. 10.1111\/pcmr.12333","journal-title":"Pigment Cell Melanoma Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2014.11.023","article-title":"Quantitative analysis of CDKN2A methylation, mRNA, and p16(INK4a) protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications","volume":"39","author":"Robaina MC","year":"2015","unstructured":"Robaina MC, Faccion RS, Arruda VO, et al.. Quantitative analysis of CDKN2A methylation, mRNA, and p16(INK4a) protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications. Leuk Res. 2015, 39:248-56. 10.1016\/j.leukres.2014.11.023","journal-title":"Leuk Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3109\/1354750X.2012.699556","article-title":"A novel p16(INK4A) mutation associated with esophageal squamous cell carcinoma in a high risk population","volume":"17","author":"Qureshi MA","year":"2012","unstructured":"Qureshi MA, Jan N, Dar NA, Hussain M, Andrabi KI. A novel p16(INK4A) mutation associated with esophageal squamous cell carcinoma in a high risk population. Biomarkers. 2012, 17:552-6. 10.3109\/1354750X.2012.699556","journal-title":"Biomarkers"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf WT","year":"2012","unstructured":"van der Graaf WT, Blay JY, Chawla SP, et al.. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012, 379:1879-86. 10.1016\/S0140-6736(12)60651-5","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.42","article-title":"BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology","volume":"30","author":"Chiang S","year":"2017","unstructured":"Chiang S, Lee CH, Stewart CJ, et al.. BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology. Mod Pathol. 2017, 30:1251-61. 10.1038\/modpathol.2017.42","journal-title":"Mod Pathol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1055\/a-0882-4116","article-title":"Sarcoma of the uterus. Guideline of the DGGG and OEGGG (S2K level, AWMF Register Number 015\/074, February 2019)","volume":"79","author":"Denschlag D","year":"2019","unstructured":"Denschlag D, Ackermann S, Battista MJ, et al.. Sarcoma of the uterus. Guideline of the DGGG and OEGGG (S2K level, AWMF Register Number 015\/074, February 2019). Geburtshilfe Frauenheilkd. 2019, 79:1043-60. 10.1055\/a-0882-4116","journal-title":"Geburtshilfe Frauenheilkd"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000001909","article-title":"Endometrial stromal sarcomas with BCOR internal tandem duplication and variant BCOR\/BCORL1 rearrangements resemble high-grade endometrial stromal sarcomas with recurrent CDK4 pathway alterations and MDM2 amplifications","volume":"46","author":"Kommoss FK","year":"2022","unstructured":"Kommoss FK, Chiang S, K\u00f6bel M, et al.. Endometrial stromal sarcomas with BCOR internal tandem duplication and variant BCOR\/BCORL1 rearrangements resemble high-grade endometrial stromal sarcomas with recurrent CDK4 pathway alterations and MDM2 amplifications. Am J Surg Pathol. 2022, 46:1142-52. 10.1097\/PAS.0000000000001909","journal-title":"Am J Surg Pathol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.02.024","article-title":"Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss","volume":"157","author":"Lin DI","year":"2020","unstructured":"Lin DI, Hemmerich A, Edgerly C, et al.. Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss. Gynecol Oncol. 2020, 157:357-66. 10.1016\/j.ygyno.2020.02.024","journal-title":"Gynecol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2017.03.002","article-title":"A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1","volume":"20","author":"Allen AJ","year":"2017","unstructured":"Allen AJ, Ali SM, Gowen K, Elvin JA, Pejovic T. A recurrent endometrial stromal sarcoma harbors the novel fusion JAZF1-BCORL1. Gynecol Oncol Rep. 2017, 20:51-3. 10.1016\/j.gore.2017.03.002","journal-title":"Gynecol Oncol Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10331","article-title":"Inactivation of p16\/CDKN2 and p15\/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer","volume":"99","author":"Kudoh K","year":"2002","unstructured":"Kudoh K, Ichikawa Y, Yoshida S, et al.. Inactivation of p16\/CDKN2 and p15\/MTS2 is associated with prognosis and response to chemotherapy in ovarian cancer. Int J Cancer. 2002, 99:579-82. 10.1002\/ijc.10331","journal-title":"Int J Cancer"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noz124","article-title":"CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas","volume":"21","author":"Appay R","year":"2019","unstructured":"Appay R, Dehais C, Maurage CA, et al.. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 2019, 21:1519-28. 10.1093\/neuonc\/noz124","journal-title":"Neuro Oncol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2008.02.013","article-title":"Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma","volume":"62","author":"Kobayashi N","year":"2008","unstructured":"Kobayashi N, Toyooka S, Yanai H, et al.. Frequent p16 inactivation by homozygous deletion or methylation is associated with a poor prognosis in Japanese patients with pleural mesothelioma. Lung Cancer. 2008, 62:120-5. 10.1016\/j.lungcan.2008.02.013","journal-title":"Lung Cancer"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100044","article-title":"High-grade endometrial stromal sarcomas with YWHAE::NUTM2 gene fusion exhibit recurrent CDKN2A alterations and absence of p16 staining is a poor prognostic marker","volume":"36","author":"Kommoss FK","year":"2023","unstructured":"Kommoss FK, Mar LM, Howitt BE, et al.. High-grade endometrial stromal sarcomas with YWHAE::NUTM2 gene fusion exhibit recurrent CDKN2A alterations and absence of p16 staining is a poor prognostic marker. Mod Pathol. 2023, 36:100044. 10.1016\/j.modpat.2022.100044","journal-title":"Mod Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/192972-poor-prognosis-in-low-grade-endometrial-stromal-sarcoma-with-cyclin-dependent-kinase-inhibitor-2a-homozygous-deletion-a-case-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T14:36:52Z","timestamp":1707748612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/192972-poor-prognosis-in-low-grade-endometrial-stromal-sarcoma-with-cyclin-dependent-kinase-inhibitor-2a-homozygous-deletion-a-case-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.54066","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,12]]}}}